3D-(6-acyl) PHAD^™

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

3D-(6-acyl) PHAD^™ has been used:

• as a synthetic adjuvant in human papillomavirus (HPV) and virus-like particles (VLPs)-based HPV vaccine preparations
• as a component of liposomes for immunizing mice with P. falciparum (Pfs25) malaria transmission-blocking vaccine antigen candidate
• in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice

2 mL Amber Glass Crimp Cap Vial (699855P-1mg)

2 mL Amber Glass Crimp Cap Vial (699855P-5mg)

5 mL Amber Glass Screw Cap Vial (699855P-10MG);5 mL Amber Glass Screw Cap Vial (699855P-25MG)

For R&D use only. Not for drug, household, or other uses.

Avanti Research is a trademark of Avanti Polar Lipids, LLC

PHAD is a trademark of Avanti Polar Lipids, LLC